Cora E Lewis1, Lawrence J Fine1, Srinivasan Beddhu1, Alfred K Cheung1, William C Cushman1, Jeffrey A Cutler1, Gregory W Evans1, Karen C Johnson1, Dalane W Kitzman1, Suzanne Oparil1, Mahboob Rahman1, David M Reboussin1, Michael V Rocco1, Kaycee M Sink1, Joni K Snyder1, Paul K Whelton1, Jeff D Williamson1, Jackson T Wright1, Walter T Ambrosius1. 1. The affiliations of the members of the writing committee are as follows: the Department of Epidemiology, School of Public Health (C.E.L.), and the Divisions of Preventive Medicine (C.E.L.) and Cardiovascular Disease (S.O.), Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham; the Clinical Applications and Prevention Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (L.J.F., J.A.C., J.K.S.); the Division of Nephrology and Hypertension, University of Utah, and Medical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City (S.B., A.K.C.); the Department of Preventive Medicine, University of Tennessee Health Science Center (W.C.C., K.C.J.), and Medical Service, Veterans Affairs Medical Center (W.C.C.), Memphis; the Department of Biostatistics and Data Science (G.W.E., D.M.R., W.T.A.), the Division of Cardiovascular Medicine (D.W.K.) and Section of Nephrology (M.V.R.), Department of Internal Medicine, and the Sticht Center for Healthy Aging and Alzheimer's Prevention and Division of Geriatric Medicine (K.M.S., J.D.W.), Wake Forest School of Medicine, Winston Salem, NC; the Division of Nephrology and Hypertension, Louis Stokes Cleveland Veterans Affairs Medical Center (M.R.), and the Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Case Western Reserve University (M.R., J.T.W.), Cleveland; and the Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans (P.K.W.).
Abstract
BACKGROUND: In a previously reported randomized trial of standard and intensive systolic blood-pressure control, data on some outcome events had yet to be adjudicated and post-trial follow-up data had not yet been collected. METHODS: We randomly assigned 9361 participants who were at increased risk for cardiovascular disease but did not have diabetes or previous stroke to adhere to an intensive treatment target (systolic blood pressure, <120 mm Hg) or a standard treatment target (systolic blood pressure, <140 mm Hg). The primary outcome was a composite of myocardial infarction, other acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular causes. Additional primary outcome events occurring through the end of the intervention period (August 20, 2015) were adjudicated after data lock for the primary analysis. We also analyzed post-trial observational follow-up data through July 29, 2016. RESULTS: At a median of 3.33 years of follow-up, the rate of the primary outcome and all-cause mortality during the trial were significantly lower in the intensive-treatment group than in the standard-treatment group (rate of the primary outcome, 1.77% per year vs. 2.40% per year; hazard ratio, 0.73; 95% confidence interval [CI], 0.63 to 0.86; all-cause mortality, 1.06% per year vs. 1.41% per year; hazard ratio, 0.75; 95% CI, 0.61 to 0.92). Serious adverse events of hypotension, electrolyte abnormalities, acute kidney injury or failure, and syncope were significantly more frequent in the intensive-treatment group. When trial and post-trial follow-up data were combined (3.88 years in total), similar patterns were found for treatment benefit and adverse events; however, rates of heart failure no longer differed between the groups. CONCLUSIONS: Among patients who were at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg, both during receipt of the randomly assigned therapy and after the trial. Rates of some adverse events were higher in the intensive-treatment group. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062.).
BACKGROUND: In a previously reported randomized trial of standard and intensive systolic blood-pressure control, data on some outcome events had yet to be adjudicated and post-trial follow-up data had not yet been collected. METHODS: We randomly assigned 9361 participants who were at increased risk for cardiovascular disease but did not have diabetes or previous stroke to adhere to an intensive treatment target (systolic blood pressure, <120 mm Hg) or a standard treatment target (systolic blood pressure, <140 mm Hg). The primary outcome was a composite of myocardial infarction, other acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular causes. Additional primary outcome events occurring through the end of the intervention period (August 20, 2015) were adjudicated after data lock for the primary analysis. We also analyzed post-trial observational follow-up data through July 29, 2016. RESULTS: At a median of 3.33 years of follow-up, the rate of the primary outcome and all-cause mortality during the trial were significantly lower in the intensive-treatment group than in the standard-treatment group (rate of the primary outcome, 1.77% per year vs. 2.40% per year; hazard ratio, 0.73; 95% confidence interval [CI], 0.63 to 0.86; all-cause mortality, 1.06% per year vs. 1.41% per year; hazard ratio, 0.75; 95% CI, 0.61 to 0.92). Serious adverse events of hypotension, electrolyte abnormalities, acute kidney injury or failure, and syncope were significantly more frequent in the intensive-treatment group. When trial and post-trial follow-up data were combined (3.88 years in total), similar patterns were found for treatment benefit and adverse events; however, rates of heart failure no longer differed between the groups. CONCLUSIONS: Among patients who were at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg, both during receipt of the randomly assigned therapy and after the trial. Rates of some adverse events were higher in the intensive-treatment group. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062.).
Authors: Jackson T Wright; Paul K Whelton; Karen C Johnson; Joni K Snyder; David M Reboussin; William C Cushman; Jeff D Williamson; Nicholas M Pajewski; Alfred K Cheung; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Srinivasan Beddhu; Lawrence J Fine; Jeffrey A Cutler; Walter T Ambrosius; Mahboob Rahman; Carolyn H Still; Zhengyi Chen; Curtis Tatsuoka Journal: Hypertension Date: 2021-11-10 Impact factor: 10.190
Authors: Paul E Drawz; Nayanjot Kaur Rai; Kristin Macfarlane Lenoir; Maritza Suarez; James R Powell; Dominic S Raj; Srinivasan Beddhu; Anil K Agarwal; Sandeep Soman; Paul K Whelton; James Lash; Frederic F Rahbari-Oskoui; Mirela Dobre; Mark A Parkulo; Michael V Rocco; Andrew McWilliams; Jamie P Dwyer; George Thomas; Mahboob Rahman; Suzanne Oparil; Edward Horwitz; Nicholas M Pajewski; Areef Ishani Journal: Kidney360 Date: 2022-05-10
Authors: Sultana Monira Hussain; Michael E Ernst; Anna L Barker; Karen L Margolis; Christopher M Reid; Johannes T Neumann; Andrew M Tonkin; Thao Le Thi Phuong; Lawrence J Beilin; Thao Pham; Enayet K Chowdhury; Flavia M Cicuttini; Julia F M Gilmartin-Thomas; Prudence R Carr; John J McNeil Journal: Hypertension Date: 2022-06-20 Impact factor: 9.897
Authors: Jordana B Cohen; Zachary A Marcum; Chong Zhang; Catherine G Derington; Tom H Greene; Lama Ghazi; Jennifer S Herrick; Jordan B King; Alfred K Cheung; Nick Bryan; Mark A Supiano; Joshua A Sonnen; William S Weintraub; Daniel Scharfstein; Jeff Williamson; Nicholas M Pajewski; Adam P Bress Journal: JAMA Netw Open Date: 2022-07-01
Authors: Bao Oanh Nguyen; Harry J G M Crijns; Jan G P Tijssen; Bastiaan Geelhoed; Anne H Hobbelt; Martin E W Hemels; W J Myke Mol; Bob Weijs; Marco Alings; Marcelle D Smit; Robert G Tieleman; Raymond Tukkie; Dirk J Van Veldhuisen; Isabelle C Van Gelder; Michiel Rienstra Journal: Europace Date: 2022-07-15 Impact factor: 5.486